Effectiveness of Noradrenaline and Albumin vs. Terlipressin andAlbumin in Treating Hepatorenal Syndrome in Patients of ChronicLiver Disease
Abstract
Objective: To compare the efficacy of noradrenaline and albumin versus terlipressin and albumin in the treatment of hepato-renal syndrome in patients with chronic liver disease.Methods
This was a randomized controlled trial conducted from 2nd August 2022 to 1st February 2023 at the Department of Medicine & Gastroenterology, Medical unit III, Services Hospital Lahore. A total of 70 patients of age 18 to 70 years, both genders, diagnosed with chronic liver disease (CLD) having HRS were included. Patients with chronic kidney disease (CKD), history of ischemic heart disease, arrhythmias or cardiomyopathy were excluded. Group A received Inj. Terlipressin 1mg x 6 hourly along with Inj. Albumin 1 mg/kg on day 1 and then 20 mg/day. Group B received Nordrenaline initially 1 mg/hour along with Inj. Albumin 1 mg/kg on day 1 and then 20mg/day. Patients were followed for 48 hours. If there was decline of serum creatinine < 1.5 mg/dl within 48 hours, then efficacy was labeled.Results
In our study, efficacy of noradrenaline and albumin was 80.0% versus 37.14% in terlipressin and albumin in treatment of hepato-renal syndrome in patients of CLD.Conclusion
This study concluded that efficacy of noradrenaline and albumin is better than terlipressin and albumin in treatment of hepato-renal syndrome in patients of chronic liver disease.Keywords:
Liver cirrhosis, hepatorenal syndrome, nor-adrenaline.Published
2025/03/10
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com